Abstract
WHO (World Health Organization) recommends countries to implement pharmacovigilance and to collect information on aDSM (active drug safety monitoring and management of adverse events-AEs).
Aim of this prospective study was to evaluate the frequency and severity of AEs to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e. bedaquiline, delamanid) and repurposed (i.e.. clofazimine, linezolid) drugs, based on the WHO aDSM project.
AEs were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.
Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% males, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall 504 AE episodes were reported: 447 (447/504, 88.7%) were classified as minor (grade 1–2) and 57 (57/504, 11.3%) as serious (grade 3–5).
The majority of the 57 serious AEs reported by 55 patients (51/57; 89.5%) ultimately resolved. Among patients reporting serious AEs some drugs held responsible were discontinued: bedaquiline in 0.35% (2/577), delamanid in 0.8% (1/121), linezolid in 1.9% (10/536) and clofazimine in 1.4% (3/213) of patients.
Serious AEs were reported in 6.9% (9/131) of patients treated with amikacin, 0.4% (1/221) with ethionamide/prothionamide, 2.8% (15/536) with linezolid and 1.8% (8/498) with cycloserine/terizidone.
The aDSM study provided valuable information but implementation needs scaling-up to support patient-centred care.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Maryandyshev has nothing to disclose.
Conflict of interest: Dr. Miliauskas has nothing to disclose.
Conflict of interest: Dr. Kuksa reports personal fees from Tibotec, personal fees from Otsuka , during the conduct of the study; personal fees from Johnson & Johnson Services Inc., outside the submitted work.
Conflict of interest: Dr. Manga has nothing to disclose.
Conflict of interest: Dr. Skrahina has nothing to disclose.
Conflict of interest: Dr. Aleksa has nothing to disclose.
Conflict of interest: Dr. Bruchfeld has nothing to disclose.
Conflict of interest: Dr. Koleva has nothing to disclose.
Conflict of interest: Dr. Piubello has nothing to disclose.
Conflict of interest: Dr. Udwadia has nothing to disclose.
Conflict of interest: Dr. Akkerman has nothing to disclose.
Conflict of interest: Dr. Bernal has nothing to disclose.
Conflict of interest: Dr. Boeree has nothing to disclose.
Conflict of interest: Dr. Cadiñanos Loidi has nothing to disclose.
Conflict of interest: Dr. Cai has nothing to disclose.
Conflict of interest: Dr. García-García has nothing to disclose.
Conflict of interest: Dr. Davidavičienė has nothing to disclose.
Conflict of interest: Dr. Denholm has nothing to disclose.
Conflict of interest: Dr. Drakšienė has nothing to disclose.
Conflict of interest: Dr. Duarte has nothing to disclose.
Conflict of interest: Dr. Elamin has nothing to disclose.
Conflict of interest: Dr. Ferrarese has nothing to disclose.
Conflict of interest: Dr. Filippov has nothing to disclose.
Conflict of interest: Dr. Garcia has nothing to disclose.
Conflict of interest: Dr. García-García has nothing to disclose.
Conflict of interest: Dr. Gaudiesiute has nothing to disclose.
Conflict of interest: Dr. Gavazova has nothing to disclose.
Conflict of interest: Dr. Gayoso has nothing to disclose.
Conflict of interest: Dr. Gruslys has nothing to disclose.
Conflict of interest: Dr. Gualano has nothing to disclose.
Conflict of interest: Dr. Hoefsloot has nothing to disclose.
Conflict of interest: Dr. Jonsson has nothing to disclose.
Conflict of interest: Dr. Khimova has nothing to disclose.
Conflict of interest: Dr. Kunst has nothing to disclose.
Conflict of interest: Dr. Laniado- Laborín has nothing to disclose.
Conflict of interest: Dr. Li has nothing to disclose.
Conflict of interest: Dr. Magis-Escurra has nothing to disclose.
Conflict of interest: Dr. Marchese has nothing to disclose.
Conflict of interest: Dr. Martínez Robles has nothing to disclose.
Conflict of interest: Dr. Matteelli has nothing to disclose.
Conflict of interest: Dr. Mazza-Stalder has nothing to disclose.
Conflict of interest: Dr. Moschos has nothing to disclose.
Conflict of interest: Dr. MUÑOZ-TORRICO has nothing to disclose.
Conflict of interest: Dr. Nakčerienė has nothing to disclose.
Conflict of interest: Dr. Nicod has nothing to disclose.
Conflict of interest: Dr. Nieto Marcos has nothing to disclose.
Conflict of interest: Dr. Palmero has nothing to disclose.
Conflict of interest: Dr. Palmieri has nothing to disclose.
Conflict of interest: Dr. Papavasileiou has nothing to disclose.
Conflict of interest: Dr. Payen has nothing to disclose.
Conflict of interest: Dr. PONTARELLI has nothing to disclose.
Conflict of interest: Dr. Rendon has nothing to disclose.
Conflict of interest: Dr. Solovic has nothing to disclose.
Conflict of interest: Dr. Souleymane has nothing to disclose.
Conflict of interest: Dr. Tadolini has nothing to disclose.
Conflict of interest: Dr. Vescovo has nothing to disclose.
Conflict of interest: Dr. Viggiani has nothing to disclose.
Conflict of interest: Dr. Yedilbayev has nothing to disclose.
Conflict of interest: Dr. Zablockis has nothing to disclose.
Conflict of interest: Dr. Zignol has nothing to disclose.
Conflict of interest: Dr. Visca has nothing to disclose.
Conflict of interest: Dr. Spanevello has nothing to disclose.
Conflict of interest: Dr. Tiberi has nothing to disclose.
Conflict of interest: Dr. Pontali has nothing to disclose.
Conflict of interest: Dr. Migliori has nothing to disclose.
Conflict of interest: Dr. Alffenaar has nothing to disclose.
Conflict of interest: Dr. Belilovski has nothing to disclose.
Conflict of interest: Dr. Borisov has nothing to disclose.
Conflict of interest: Dr. Caminero has nothing to disclose.
Conflict of interest: Dr. D'Ambrosio has nothing to disclose.
Conflict of interest: Dr. Danila has nothing to disclose.
Conflict of interest: Dr. Diktanas reports personal fees from Otsuka, grants from Janssen (Sirturo), outside the submitted work.
Conflict of interest: Dr. Escobar Salinas has nothing to disclose.
Conflict of interest: Dr. Vinicio has nothing to disclose.
Conflict of interest: Dr. Mustafa Hamdan has nothing to disclose.
Conflict of interest: Dr. Smite has nothing to disclose.
Conflict of interest: Dr. van den Boom has nothing to disclose.
Conflict of interest: Dr. Quiros has nothing to disclose.
Conflict of interest: Dr. Centis has nothing to disclose.
Conflict of interest: Dr. Codecasa has nothing to disclose.
Conflict of interest: Dr. Dalcolmo has nothing to disclose.
Conflict of interest: Dr. Dara has nothing to disclose.
Conflict of interest: Dr. Davies Forsman has nothing to disclose.
Conflict of interest: Dr. Gomez Rosso has nothing to disclose.
Conflict of interest: Dr. Saderi has nothing to disclose.
Conflict of interest: Dr. Zhurkin has nothing to disclose.
Conflict of interest: Dr. Cebrian Gallardo has nothing to disclose.
Conflict of interest: Dr. De Los Rios Jefe has nothing to disclose.
Conflict of interest: Dr. Sotgiu has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2019